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1 |  SKELETAL MUSCLE IN 
METABOLIC DISEASE AETIOLOGY
Metabolic diseases such as obesity, insulin resistance, and 
type 2 diabetes mellitus (T2DM) pose a growing threat to 
global health (Chobot et al., 2018; Zimmet et al., 2016). These 
diseases are associated with increased morbidity and mortal-
ity (Chobot et al., 2018), and recent evidence suggests they 
are also associated with the development of severe symptoms 
in response to contemporary infectious diseases such as 
COVID-19 (Dietz & Santos-Burgoa, 2020; Drucker, 2020). 
Characterizing the etiology of metabolic diseases may be key 
to unlocking therapeutic strategies to improve global health.
Skeletal muscle dysfunction is part of a myriad of dis-
ruptions to physiological homeostasis in metabolic diseases 
(Gabriel & Zierath, 2017, 2019). This tissue plays a key role 
in metabolic diseases as it accounts for the largest quantita-
tive component of energy expenditure in the body (DeFronzo 
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Abstract
The prevalence of obesity and type 2 diabetes has increased substantially in recent 
years creating a global health burden. In obesity, skeletal muscle, the main tissue re-
sponsible for insulin-mediated glucose uptake, exhibits dysregulation of insulin sign-
aling, glucose uptake, lipid metabolism, and mitochondrial function, thus, promoting 
type 2 diabetes. The phospholipase A2 (PLA2) enzyme family mediates lipid signal-
ing and membrane remodeling and may play an important role in metabolic disorders 
such as obesity, diabetes, hyperlipidemia, and fatty liver disease. The PLA2 family 
consists of 16 members clustered in four groups. PLA2s hydrolyze the sn-2 ester bond 
of phospholipids generating free fatty acids and lysophospholipids. Differential tis-
sue and subcellular PLA2 expression patterns and the abundance of distinct fatty acyl 
groups in the target phospholipid determine the impact of individual family members 
on metabolic functions and, potentially, diseases. Here, we update the current knowl-
edge of the role of the PLA2 family in skeletal muscle, with a view to their potential 
for therapeutic targeting in metabolic diseases.
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& Tripathy,  2009). Importantly, skeletal muscle is also re-
sponsible for approximately 25% of postprandial glucose 
disposal and 85% of glucose uptake during hyperinsulin-
emia (DeFronzo & Tripathy, 2009; Gabriel & Zierath, 2017). 
Metabolic systems within skeletal muscle that are prone 
to dysregulation in the context of metabolic diseases in-
clude glucose metabolism, insulin signaling, mitochondrial 
function, and lipid metabolism (Gabriel & Zierath,  2019). 
Defects in the canonical insulin signaling pathway that un-
derlie pathological skeletal muscle insulin resistance can 
manifest through reduced phosphorylation of Insulin recep-
tor substrate 1 (IRS1), Protein kinase B (AKT) (at Thr308), 
AKT substrate 160 (AS160), and decreased activity of 
Phosphoinositide 3-kinases (PI3Ks) and glycogen synthase 
(Karlsson & Zierath, 2007). These signaling and enzymatic 
dysfunctions result in reduced insulin-stimulated transloca-
tion of glucose transporter (GLUT) 4 to the plasma mem-
brane (Karlsson & Zierath, 2007) and, thus, increased blood 
glucose. Additionally, mitochondria in the skeletal muscle 
of people with T2DM are reduced in size, total volume, 
and total oxidative capacity compared to healthy subjects 
(Gabriel & Zierath, 2017). This attenuated oxidative capac-
ity may play a role in local insulin resistance and glucose 
intolerance via reduced oxidation, and dysfunctional metabo-
lism of intramuscular lipid species (Ruegsegger et al., 2018). 
Altered processing of lipid species within skeletal muscle is 
often observed during obesity, T2DM, and other metabolic 
diseases with disrupted processing of species including dia-
cylglycerols (DAGs) and ceramides associated with defects 
in the insulin signaling pathway (Coen & Goodpaster, 2012; 
Goodpaster & Wolf,  2004). An overarching link between 
these molecular disorders observed in metabolic diseases 
may be related to defects in cellular phospholipid metabo-
lism localized to the sarcoplasmic reticulum, mitochondria, 
plasma membrane, lipid droplets, and other important myo-
cellular components (Funai et al., 2016; Heden et al., 2016).
2 |  THE PHOSPHOLIPASE A2 
FAMILY
Originally identified in the late 1800s as being responsible for 
the lytic action of snake venom, phospholipase A2 (PLA2) is 
one of the most studied, and best characterized, enzymes (re-
view in Dennis et al., 2011). It is now clear that there is not 
just a single PLA2, but multiple isozymes, and that the PLA2 
family comprises 16 enzymes, and multiple subgroups, 
which catalyze the hydrolysis of membrane phospholipids 
and exert diverse roles in lipid metabolism. As technology 
has advanced, and new forms of PLA2s have been discov-
ered, these have been named based on their pattern of di-
sulfide bonds and order of discovery. This group numbering 
process and the long history of this family of enzymes have 
been extensively detailed elsewhere (Dennis et al., 2011), but 
can broadly be broken down into (summarized in Table 1):
a. Secreted PLA2s (sPLA2s, Groups GI-III, V, and IV-XIV)—
Originally identified in cobra/rattlesnake venom and as a 
key digestive pancreatic enzyme in cows; only Groups 
IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA, and XIIB 
are present in mammals. These secreted proteins exert 
diverse actions including the resolution of inflammation by 
driving production of pro-resolving lipid mediators (GIID), 
facilitation of mast cell maturation via a prostaglandin D2 
pathway (GIII), and promotion of Th2 immunity (GV). 
sPLAs also play a key role in lipoprotein metabolism 
breaking down oxidized lipids contained in low- and 
high-density lipoproteins, and, thus, contribute to dyslip-
idemia, obesity, and insulin resistance (Sato et  al.,  2014).
b. Cytosolic PLA2s (cPLA2s, Group IV)—With the first 
cPLA2 identified in 1986, this group now comprises six, 
distinct calcium-dependent isoenzymes (A(α), B(β), C(γ), 
D(δ), E(ε), and F(ζ)), sharing no more than ~30% homology 
and exhibiting important differences in tissue expression, 
regulatory mechanisms, and function. For instance, cPLAα 
promotes the expansion of lipid droplets and adipogensis 
playing a role in metabolic diseases (Guijas et al., 2014; Peña 
et al., 2016). The function of the other cPLA2s and its impli-
cation in metabolism regulation is still under investigation.
c. Calcium-independent PLA2s (iPLA2s, Group VI)—Having 
been initially purified and characterized in macrophages in 
1994, there are now six distinct iPLA2 family members (A 
(β), B(γ), C(δ), D(ε), E(ζ), F(η)) all exhibiting calcium-in-
dependent enzymatic activity. The functions of this group 
are diverse including metabolic functions such as acylation 
of fatty acids in adipose tissue, promotion of B-cell apopto-
sis, and regulation of skeletal muscle insulin signaling and 
GLUT4 translocation (Ramanadham et al., 2015).
d. Platelet activating factor acetyl hydrolases (PAH-AH, 
Groups VII and VIII)—This group of enzymes, which 
hydrolyze the acetyl group from the sn-2 position of 
platelet activation factor, a phospholipid activator which 
regulates platelet aggregation, inflammation, and leuko-
cyte function can be further categorized into (a) LpPLA2, 
secreted plasma enzyme associated with the concentra-
tion levels of both high- and low-density lipoproteins in 
humans; and (b) PAF-AH II, an intracellular PAF acetyl 
hydrolase; and (c) PAF-AH Ib, a brain intracellular 
protein complex with multiple subunits. The metabolic 
function of this group has not been established yet.
e. Lysosomal PLA2s (LPLA2, Group XV)—Originally 
identified as 1-O-acylceramide synthase (ACS), subse-
quent characterization determined that this water-soluble 
glycoprotein had predominantly PLA2-like activity with 
specificity for phosphatidylethanolamine (PE) and phos-
phatidylcholine (PC). The function of LPLA2 is mainly the 
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degradation of phospholipids in the lysosome and no meta-
bolic function has been described for this group.
f. Adipose-specific PLA2 (AdPLA, Group XVI)—Initially 
characterized as a tumor suppressor, this protein exhib-
its calcium-independent PLA1 and PLA2 activity and is 
ubiquitously expressed with high expression in adipose 
tissue. Aside from its role as tumor suppressor, AdPLA 
plays a metabolic function regulating lypolysis in adipose 
tissue (Jaworski et al., 2009).
3 |  NON-CYTOSOLIC PLA2s AND 
METABOLIC DISEASES
Different members of the PLA2 family were associated with 
metabolic diseases such as obesity, T2DM, fatty liver dis-
ease, and hyperlipidemia (Hui, 2012). In general, the putative 
cause of this association is the accumulation of active lipid 
molecules driven by changes in PLA2-mediated phospholi-
pase activity (Dennis et al., 2011; Hui, 2012). Here, we aim 
to describe the different PLA2s associated with metabolic 
diseases with a focus on recent advances (summarized in 
Table 1).
For this purpose, the PLA2 family members have been 
divided into non-cytosolic and cytosolic PLA2s.
While non-cytosolic PLA2s have been extensively stud-
ied for their role in generating lipid mediators, the sPLA2s 
is the largest group and its most relevant members associ-
ated with metabolic diseases are group V (sPLA2-V) and 
group IIE (sPA2-IIE) (Sato et al., 2016); expressed highly in 
mouse white adipose tissue after high-fat-diet (HFD) (Sato 
et al., 2014). Notably, sPLA2-V knockout mice exhibited in-
creased adiposity, insulin resistance, adipose tissue inflam-
mation, hepatic steatosis, and hyperlipidemia after HFD. This 
was due to a reduction in the hydrolysis of low-density lipo-
proteins that led to an increase in M1 macrophages (pro-in-
flammatory) (Sato et  al.,  2014). In contrast, sPLA2-IIE 
knockout mice were protected from the HFD-induced weight 
gain and fatty liver disease due to a modification in the com-
position of lipoproteins that reduced fat accumulation (Sato 
et  al.,  2014). Therefore, high levels of sPLA2-V drove an-
ti-obesity and anti-inflammatory effects and high levels of sP-
LA2-IIE led to the opposite effect (Sato et al., 2016). Another 
sPLA2s, group IB (sPLA2-IB) known for its activity in the 
digestive tract, was implicated in promoting obesity and insu-
lin resistance (Sato et al., 2016), as well as hyperlipidemia by 
increasing the production of very-low density lipoproteins, 
precursors of low-density lipoproteins, and decreasing the 
elimination of triglyceride-rich lipoproteins in mice (Hollie 
& Hui,  2011). Polymorphisms in group IIA (sPLA2-IIA) 
have recently been linked with a high risk of developing met-
abolic syndrome and T2DM (Monroy-Muñoz et  al., 2017). 
Furthermore, mice expressing the human PLA2-IIA variant 
were more insulin sensitive and resistant to weight gain after 
HFD challenge due to an elevated metabolic rate that was not 
caused by increased physical activity (Kuefner et al., 2017). 
Finally, although the implication of group X (sPLA2-X) in 
metabolic diseases is still uncertain (Sato et  al., 2016), sP-
LA2-X activity was associated with suppression of insulin 
secretion in mice (Shridas et al., 2014).
Another non-cytosolic PLA2 group relevant to metabolic 
diseases is the iPLA2s (Ramanadham et  al.,  2015). One 
of its best characterized members, group VIE (iPLA2ζ), 
plays a key role in triglyceride catabolism and energy ho-
meostasis (Trites & Clugston,  2019). Over 40 mutations 
in this gene were classified as a neutral lipid storage dis-
ease with myopathy (NLSDM), a rare autosomal recessive 
disease (Trites & Clugston, 2019). Extensive phenotyping 
of several transgenic iPLA2ζ models demonstrated that 
adipose-specific or global deletion with rescued cardiac 
iPLA2ζ led to a beneficial metabolic effect without any 
detrimental cardiac phenotype (Trites & Clugston, 2019). 
Recently, a selective inhibitor targeting adipose and liver 
iPLA2ζ transiently reversed HFD-induced obesity, insulin 
resistance, and fatty liver disease without related cardiac 
complications in mice (Schweiger et al., 2017). However, 
the effects of this drug were not recapitulated in human 
adipocytes. This lack of translation was considered note-
worthy by the authors as the protein sequence of mouse 
and human iPLA2ζ is 84% similar (Schweiger et al., 2017), 
therefore, this supports the necessity of further structur-
al-functional studies. Nevertheless, iPLA2ζ may represent 
a possible therapy for treating obesity and obesity-associ-
ated diseases through its actions in other tissues. Group 
VIA (iPLA2β) was recently associated with body fat per-
centage, and consequently, with increased T2DM risk in a 
genome-wide association study (GWAS) (Lu et al., 2016). 
Genetically obese mice lacking iPLA2β were protected 
from obesity, insulin resistance, dyslipidemia, and fatty 
liver (Deng et al., 2016). The authors proposed that the pro-
tection from obesity could be partially explained by an im-
pairment in adipocyte differentiation, previously described 
in 3T3-L1 pre-adipocytes treated with iPLA2β small-inter-
fering RNA (Su et al., 2004). Furthermore, the protection 
from fatty liver was shown to be achieved by the remod-
eling of hepatic phospholipid composition toward the re-
plenishment of PUFA-containing phospholipids (Deng 
et al., 2016). Group VIB (iPLA2γ) is another iPLA2 with 
a role in diet-induced weight gain and insulin resistance 
due to the upregulation of skeletal muscle mitochondrial 
fatty acid oxidation described using knockout mice (Song 
et al., 2010). Finally, a genetic variant (L148) of group VID 
(iPLA2ε) associated with fatty liver disease (Ramanadham 
et al., 2015) was recently reported to have a higher impact 
in this disease in the presence of other risk factors such as 
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obesity and visceral adiposity (Bruschi et  al.,  2017). The 
accumulation of iPLA2ε in lipid droplets was hypothesized 
as the causal mechanism for this association; drugs target-
ing iPLA2ε are under development as a therapeutic strat-
egy for treating fatty liver disease (BasuRay et al., 2019).
Regarding the PAF-AH, the plasmatic levels of group 
VIIA (Lp-PLA2) were associated with T2DM (Fortunato 
et  al.,  2014). However, this was complicated by a lack of 
association between Lp-PLA2 and T2DM in another study 
that found a positive association with heart disease (Charniot 
et al., 2013).
Finally, group XVI (AdPLA) is an adipose-specific PLA2 
that was reported to play a role in obesity by downregulating 
lipolysis (Jaworski et al., 2009).
In conclusion, the non-cytosolic PLA2s have been im-
plicated in metabolic diseases through population stud-
ies and the use of transgenic animal models. However, the 
exact mechanisms underpinning these effects remain to be 
elucidated.
4 |  CYTOSOLIC PLA2s AND 
METABOLIC DISEASES
Group IVA (cPLA2α), the best characterized cPLA2, inter-
acts with membranes such as those found in the Golgi, en-
doplasmic reticulum, and lipid droplets. cPLA2α activity 
requires calcium stimulation, binding with anionic phospho-
lipids or phosphorylation by mitogenic-activated protein ki-
nases (Guijas et al., 2014; Ohto et al., 2005). The association 
of cPLA2α with lipid droplet biogenesis underlines a possible 
role of cPLA2α in metabolic diseases (Guijas et al., 2014). 
Specifically, cPLA2α facilitates the expansion of the lipid 
droplets from the endoplasmic reticulum following exog-
enous lipid overload, stress stimulus, or cellular activation 
(Guijas et al., 2014). Therefore, cPLA2α activity promotes 
the accumulation of lipid droplets in key tissues, and may 
act as a mechanism for developing metabolic diseases (Xu 
et al., 2018).
In the last decade, the role of cPLA2α in pathophysio-
logical conditions such as fatty liver disease and obesity has 
been studied (Ii et al., 2008, 2009; Peña et al., 2016). For 
example, knockout of cPLA2α in male mice led to reduced 
body weight, epididymal fat mass, and hepatic triglyceride 
levels (Ii et  al.,  2008), and protection from HFD-induced 
hepatomegaly and fat accumulation compared to wild-type 
mice (Ii et  al.,  2009). Further histological analysis of the 
epidydimal fat and liver of the cPLA2α knockout mice 
showed smaller adipocytes and reduced vacuolization of the 
hepatocytes. More recently, a cPLA2α inhibitor prevented 
fatty liver and hepatic fibrosis in mice (Kanai et al., 2016). 
Related to obesity, cPLA2α was implicated in the early 
events of adipogenesis of multipotent adipose-derived stem 
cells (MEFs), NIH/3T3 cell line, and adipose predetermined 
3T3-L1 cell line (Peña et al., 2016). In the same study, the 
role of cPLA2α in HFD-induced obesity was described in 
vivo (Peña et al., 2016). Male cPLA2α knockout mice had 
reduced white adipose tissue mass compared to control 
mice after HFD. This reduction in white adipose tissue mass 
was associated with a decrease in adipocyte number, and an 
increase in the frequency of small adipocytes, both of which 
correlated with decreased adipose-tissue triglycerides and 
cholesteryl esters, and increased adipose-tissue phospho-
lipids in the knockout mice. In addition, decreased expres-
sion of adipocyte transcription factors such as C/EBPβ, 
SREBP-1c, and Adipophilin was reported in the white ad-
ipose tissue of the cPLA2α knockout mice. In summary, 
cPLA2α plays a role in promoting fat accumulation in adi-
pose tissue and liver possibly by regulating the biogenesis 
of lipid droplets and/or adipogenesis and, therefore, it could 
be a therapeutic target for obesity and other obesity-related 
diseases such as fatty liver disease.
Another relevant cPLA2 isoform is group IVE (cPLA2ε, 
gene name: Pla2g4e). This enzyme plays a role in the endo-
somal and lysosomal system, where it is specifically involved 
in the Clathrin-independent endocytic/recycling (CIE) route 
mediated by ARF6 GTPase (Capestrano et  al.,  2014; Ohto 
et al., 2005). Pla2g4e expression was upregulated in the liver 
of mice by HFD feeding (Song et  al.,  2012). Furthermore, 
the Pla2g4e locus was implicated in circulating phospho-
choline levels in mice through a GWAS across 100 strains 
of mice (Parks et  al.,  2015). Therefore, Pla2g4e could be 
implicated in obesity and insulin resistance, as plasma 
phosphocholine levels were negatively associated with 
these conditions (Palomino-Schätzlein et  al.,2019; Parks 
et al., 2015). Overexpression of NYGGF4, a factor associated 
with obesity-induced insulin resistance, drove hypomethyla-
tion of Pla2g4e in 3T3-L1 adipocytes (Yang et al., 2012). As 
epigenetic processes have been described for T2DM (Zhou 
et al., 2018), the regulation of Pla2g4e by this process in the 
NYGGF4-overexpressing 3T3-L1 cells is consistent with a 
potential role in adipose insulin resistance. Unpublished data 
also suggested that the PLA2G4E locus exhibited altered 
methylation in adipose tissue in obesity (Woo et al.). Notably, 
PLA2G4E was a hypomethylated gene in the pancreatic is-
lets of humans with T2DM (Dayeh et al., 2014) suggesting 
that control of this locus by epigenetic mechanisms may be 
an important feature of gene regulation in tissues associated 
with metabolic diseases. Taken together, these findings im-
plicate a role for cPLA2ε in obesity and T2DM potentially 
at genetic, epigenetic, and functional-gene expression level.
In conclusion, as well as non-cytosolic PLA2s, cPLA2s 
play a role in metabolic diseases. Although research on this 
topic has focused on the isoform cPLA2α, emerging evidence 
suggests other isoforms such as cPLA2ε may be involved in 
the etiology of these diseases.
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5 |  THE ROLE OF PLA2s 
IN SKELETAL MUSCLE AND 
METABOLIC DISEASES
The PLA2 family and its role in metabolic diseases has been 
extensively described with a focus on the dysregulation oc-
curring in adipose tissue and liver. Although skeletal muscle 
is a key tissue in the development and progression of meta-
bolic diseases (Stump et  al.,  2006), the role that the PLA2 
family plays in skeletal muscle during this disease state has 
not been fully elucidated. Therefore, in this section, we will 
highlight the key findings demonstrating a role of the PLA2 
family in regulating skeletal muscle metabolism in metabolic 
diseases and discuss the putative mechanism (summarized in 
Table 1 and Figure 1).
To date, some PLA2s implicated in metabolic diseases 
were associated with altered insulin sensitivity. As skeletal 
muscle accounts for the majority of the insulin-stimulated 
glucose uptake (DeFronzo & Tripathy,  2009; Gabriel & 
Zierath, 2019), it is plausible that the effect that PLA2s have 
on insulin resistance/sensitivity would be due to downstream 
effects in skeletal muscle. For instance, genetically deletion 
and pharmacologically inhibition of iPLA2ζ were associated 
with improved insulin sensitivity after chow diet or HFD 
(Schweiger et al., 2017; Trites & Clugston, 2019) due to in-
creased insulin signaling and GLUT4 translocation in mouse 
skeletal muscle (Kienesberger et al., 2009). However, these ef-
fects observed in vivo were not recapitulated ex vivo suggesting 
that systemic factors, such as serum RBP4, contributed to the 
skeletal muscle insulin sensitivity (Kienesberger et al., 2009). 
Furthermore, some of the PLA2s implicated in metabolic dis-
eases are highly expressed in skeletal muscle (summarized in 
Table 1) suggesting that PLA2s could play a direct role in reg-
ulating skeletal muscle metabolism and function.
F I G U R E  1  Role of PLA2s in regulating skeletal muscle metabolism and function in metabolic diseases. PLA2s impair skeletal muscle 
metabolism in the context of metabolic diseases through the disruption of insulin signaling, lipid metabolism, mitochondrial function, IGF-1 
signaling (muscle growth), and direct effects on GLUT4 translocation. iPLA2ζ and Lp-PLA2 play a role in downregulating skeletal muscle insulin 
signaling leading to insulin resistance in metabolic diseases (Kienesberger et al., 2009; Schweiger et al., 2017; Trites & Clugston, 2019; Wang 
et al., 2009). In this context, Lp-PLA2 also increases skeletal muscle triglyceride content (Wang et al., 2009). iPLA2γ upregulates mitochondrial 
fatty acid oxidation contributing to the increase in mitochondrial stress signals leading to obesity and insulin resistance (Song et al., 2010). cPLA2α 
downregulates IGF-1-dependent skeletal muscle growth which is associated with the development of metabolic diseases (Haq et al., 2003; Park 
& Yoon, 2013). Finally, cPLA2ε has independently been associated with trafficking processes (Capestrano et al., 2014) and metabolic diseases 
(Dayeh et al., 2014; Parks et al., 2015; Song et al., 2012; Woo et al.; Yang et al., 2012); therefore, cPLA2ε could downregulate skeletal muscle 
GLUT4 translocation leading to impaired glucose uptake. A continuous arrow indicates PLA2s with a demonstrated role in skeletal muscle 
impairment and a discontinuous arrow indicates tentative links between PLA2s and skeletal muscle metabolism and function. A red arrow indicates 
the downregulation and a blue arrow indicates the upregulation of the processes regulating skeletal muscle metabolism and function in metabolic 
diseases. Figure created using www.BioRender.com
8 of 11 |   PRUNONOSA CERVERA Et Al.
Studies have specifically investigated the alterations in 
skeletal muscle metabolism or function caused by PLA2s 
in metabolic diseases. Regarding the non-cytosolic PLA2s, 
skeletal muscle-specific Lp-PLA2 knockout mice exhibited 
improved skeletal muscle insulin sensitivity due to an in-
crease in insulin signaling and a decrease in triglyceride 
content with increased Akt, but not IRS1 or PI3K (both up-
stream of Akt) phosphorylation in skeletal muscle (Wang 
et al., 2009). However, insulin resistance in adipose tissue, 
liver, and heart that led to overall systemic insulin resis-
tance, and obesity was observed in skeletal muscle-specific 
Lp-PLA2 knockout mice (Wang et al., 2009). The authors 
speculated that this could be caused by an increase in the 
transport of TG-rich lipoproteins to tissues such as adi-
pose tissue, liver, and heart as skeletal muscle LpPLA2-
dependent lipid catabolism was impaired. Furthermore, 
mice lacking iPLA2γ were protected from diet-induced 
obesity and insulin resistance and exhibited dysfunctional 
skeletal muscle mitochondria compared to wild-type mice 
following HFD (Song et  al.,  2010). Specifically, iPLA2γ 
knockout mice exhibited decreased mitochondrial fatty 
acid oxidation in skeletal muscle and liver. The reduc-
tion in skeletal muscle fatty acid oxidation was attributed 
to an increase in mitochondrial cardiolipin (CL) content 
and heterogeneity. CL is a mitochondrial phospholipid 
that plays a role in the formation of the electron transport 
chain complexes and this may be one mechanism through 
which iPLA2γ regulated skeletal muscle metabolism (Yoda 
et al., 2010). In concordance with previous reports (Koves 
et al., 2008; Muoio & Newgard, 1455–1456, 2008.), the au-
thors hypothesized that the impairment in skeletal muscle 
mitochondrial fatty acid oxidation could have decreased the 
production of mitochondrial stress signals protecting iP-
LA2γ knockout mice from diet-induced obesity and insulin 
resistance (Song et al., 2010).
Finally, less is known regarding a role of cPLA2s in skel-
etal muscle metabolism. To date, one study demonstrated 
that cPLA2α regulates normal or pathological muscle growth 
through the insulin-like growth factor (IGF)-1 pathway (Haq 
et  al.,  2003). Mechanistically, skeletal muscle growth and 
metabolism pathways share common signaling mechanisms, 
and an increase in skeletal muscle mass is negatively associ-
ated with metabolic diseases (Park & Yoon, 2013). Therefore, 
cPLA2α could play a role in metabolic diseases by downreg-
ulating skeletal muscle growth. In terms of the other cPLA2s, 
cPLA2ε has a described role in metabolic diseases (Dayeh 
et al., 2014; Parks et al., 2015; Song et al., 2012; Woo et al.,; 
Yang et al., 2012) and is highly expressed in mouse skeletal 
muscle (Trites & Clugston, 2019). Taking into account its as-
sociation with intracellular trafficking processes (Capestrano 
et al., 2014), cPLA2ε could feasibly play a role in the regu-
lation of skeletal muscle GLUT4 translocation (Antonescu 
et al., 2008; Capestrano et al., 2014).
Overall, more work is required to fully determine the 
role that PLA2s play in skeletal muscle metabolism in the 
context of metabolic diseases. Dysregulated processing of 
fatty acid intermediates within the skeletal muscle can lead 
to deleterious metabolic outcomes (Alhindi et  al.,  2019; 
Gabriel et al., 2017; Gabriel & Zierath, 2017), and finding 
strategies to protect against this in metabolic diseases is a 
crucial area of future research. With this in mind, it is nota-
ble that iPLA2ζ null mice were protected from diet-induced 
obesity and insulin resistance due to the upregulation of in-
sulin signaling, and more work should be done to assess the 
translatability of this finding. Given the important role that 
calcium signaling plays in skeletal muscle and metabolic 
diseases (Lanner et  al.,  2006), calcium-dependent cPLA2s 
may be an important target of future research in this topic. 
Of particular importance is likely to be cPLA2s that interact 
with tubule-mediated transport (Ohto et al., 2005), as this dy-
namic process is crucial in regulating skeletal muscle glucose 
uptake via modulation of several signaling and transport pro-
teins such as GLUT4. There may be other, not yet fully char-
acterized PLA2s involved in modulating this process within 
skeletal muscle. For example, emerging evidence suggests 
cPLA2ε may regulate this process (Antonescu et al., 2008; 
Capestrano et al., 2014), but its role has not been fully char-
acterized in skeletal muscle.
6 |  SUMMARY
The prevalence of metabolic diseases such as obesity and 
T2DM has exponentially increased over the recent years, 
becoming a global health problem (Chobot et  al.,  2018; 
Zimmet et al., 2016). One of the multiple disruptions during 
the development of metabolic diseases take place in skeletal 
muscle (Gabriel & Zierath, 2019), where insulin signaling, 
glucose uptake, lipid metabolism, and mitochondria become 
dysfunctional (Gabriel & Zierath, 2019). The PLA2 family 
has been associated with metabolic diseases such as obesity, 
T2DM, hyperlipidemia, and fatty liver disease (Hui, 2012). 
However, this association has poorly been described with a 
focus on skeletal muscle, a key metabolic organ. Thus, here, 
we aim to review recent evidences that associate PLA2s with 
metabolic diseases while demonstrating a role of PLA2s in 
regulating skeletal muscle metabolism and function in meta-
bolic diseases. In conclusion, the implication of PLA2s in 
metabolic diseases has been extensively demonstrated with a 
notable role of these enzymes in skeletal muscle. Regarding 
non-cytosolic PLA2s, iPLA2ζ was shown to downregulate 
insulin signaling and GLUT4 translocation leading to in-
sulin resistance in mouse skeletal muscle (Kienesberger 
et al., 2009; Trites & Clugston, 2019). Lp-PLA2 impaired in-
sulin sensitivity and increased triglyceride content in mouse 
skeletal muscle, but had a converse effect in overall systemic 
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insulin resistance due to its effects in other metabolic tis-
sues (Wang et  al.,  2009). iPLA2γ was found to upregulate 
skeletal muscle mitochondrial fatty acid oxidation leading 
to obesity and insulin resistance in mice (Yoda et al., 2010). 
In the case of cPLA2s, it is plausible that cPLA2α contrib-
ute to metabolic diseases because of its role in negatively 
regulating skeletal muscle growth (Haq et  al.,  2003; Park 
& Yoon,  2013) and cPLA2ε may regulate skeletal muscle 
GLUT4 translocation due to its role in membrane trafficking 
observed in HeLa cells (Antonescu et al., 2008; Capestrano 
et al., 2014), putatively leading to decreased glucose uptake. 
However, the mechanism underlying the effect of PLA2s 
in skeletal muscle, especially in atypical isoforms, requires 
further characterization. Further studies using animal models 
with skeletal muscle-specific alterations in PLA2s are essen-
tial to understand the role of this diverse family in skeletal 
muscle in addition to providing vital mechanistic evidence. 
Uncovering the mechanism behind the role that these en-
zymes play in skeletal muscle may help to identify targets for 
further development of therapeutic approaches for metabolic 
diseases.
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